Curevac is based on a cancer vaccine | News

Biotechnology Curevac from Tubingen continues to grapple with the costs of the failed Corona mRNA vaccine last year. Now, cancer vaccines should help Curevac succeed.

Curevac said the first quarter of 2022 was still influenced by the effects of previous commitments for a first-generation vaccine candidate (CVnCoV). We are now focused on further cost control.

Loss before tax was EUR 15.2 million in the first quarter of 2022 after EUR 112.2 million in 2021. Revenue increased to EUR 24.4 million, EUR 14.4 million more than in the same period of the previous year .

Register now and buy a Curevac share

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

Curevac began the clinical trial of its new vaccine candidate (CV2CoV) against Corona in late March 2022. Curevac began developing a new vaccine with its UK partner, the pharmaceutical company Glaxo-Smithkline (GSK). According to Curevac, data from a new Phase 1 study are expected in the second half of 2022.

In addition, Curevac would also like to use mRNA technology for cancer vaccines. Together with myNEO NV, Curevac aims to identify specific antigens on the surface of tumors in order to develop new mRNA immunotherapies. To achieve this goal, myNEO will use its biological datasets and an integrated machine learning and bioinformatics platform to identify specific antigens and evaluate them for the expected strong immune response.

Curevac inventory test resistance

Curevac shares have been able to stabilize at around $ 15 for over a year after a significant drop in price. The MACD (Momentum) may even slightly rebound and signal a slight increase. The resistance is currently being tested at around $ 20, a breakthrough could give the stock market a new boost. The next support is around $ 14.

Curevac’s success can be attributed purchase of shares participate. Brave investors can get leverage with Buy CFDs get involved.

It’s that simple to buy stocks on eToro.

The eToro platform offers traders from all over the world the unique opportunity to add shares to their portfolio. From the beginning of 2018, each BUY non-leveraged order causes eToro to buy the underlying asset; it will then be held on behalf of the client. This also applies to cases where you invest in CopyPortfolio or copy an investor: if the copied investor buys shares, you automatically own a portion of his share portfolio.

Trade stocks with eToro, here are the advantages:

  • trust Your shares will be held in your name in an EU regulated company.
  • insurance Your deposit and related assets are insured under CySEC’s Terms of Use.
  • dividends If the company pays dividends, investors will be allocated an appropriate dividend.
  • No care fees Buying stocks on eToro means you no Pay storage and ordering fees and commissions. There is a bid-ask spread when buying and selling stocks.
  • Easy-to-use Your warehouse is always available online and via the app.
  • diversification Create a portfolio of stocks, cryptocurrencies, commodities, and more.

Register now and buy stocks

About eToro:

For over a decade, eToro has been at the forefront of the global fintech revolution. It is the world’s leading social trading network, with millions of registered users and a host of innovative trading and investing tools. Since the beginning of 2018, eToro allows you to buy and sell stocks.

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

advertisement

Leave a Comment